Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

Yuhan Corporation announced on the 30th of May that it has signed an in-license agreement with J INTS BIO for a Tyrosine Kinase Inhibitor targeting HER2, ‘JIN-A04’.